Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Authors

Danny Rischin, Peter MacCallum Cancer Centre
Leonel Hernandez-Aya, Washington University School of Medicine in St. Louis
et al

Journal

Journal for Immunotherapy of Cancer

Publication Date

6-1-2020

Volume

8

Issue

1

First Page

e000775

Document Type

Open Access Publication

DOI

10.1136/jitc-2020-000775

Rights and Permissions

Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 Jun;8(1):e000775. doi: 10.1136/jitc-2020-000775. https://jitc.bmj.com/content/8/1/e000775.long Copyright 2021 The Authors This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Recommended Citation

Rischin, Danny; Hernandez-Aya, Leonel; and et al, "Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing." Journal for Immunotherapy of Cancer. 8, 1. e000775 (2020).
https://digitalcommons.wustl.edu/oa_4/108